



Antimalarial activity of 10-alkyl/aryl esters and -aminoethylethers of artemisinin

Theunis T. Cloete^a, Henk J. Krebs^a, Julie A. Clark^b, Michele C. Connelly^b, Amy Orcutt^b, Martina S. Sigal^b, R. Kiplin Guy^b, David D. N'Da^{a,*}

^a Department of Pharmaceutical Chemistry, North-West University, Potchefstroom 2520, South Africa

^b Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mailstop 1000, Memphis, TN 38105-3678, USA

ARTICLE INFO

Article history:

Received 10 August 2012

Available online 3 November 2012

Keywords:

Ozonide

Artemether

Artesunate

Plasmodium falciparum

Cytotoxicity

ABSTRACT

A series of *n*-alkyl/aryl esters were synthesized and their *in vitro* antiplasmodial activity was measured alongside that of previously synthesized aminoethylethers of artemisinin ozonides against various strains of *Plasmodium falciparum*. The cytotoxicity against human cell lines was also assessed. The esters were synthesized in a one-step reaction by derivatization on carbon C-10 of dihydroartemisinin. Both classes were active against both the 3D7 and K1 strains of *P. falciparum*, with all compounds being significantly more potent than artemether against both strains. The majority of compounds possessed potency either comparable or more than artesunate with a high degree of selectivity towards the parasitic cells. The 10 α -*n*-propyl **11** and 10 α -benzyl **18** esters were the most potent of all synthesized ozonides, possessing a moderate (~3-fold) and significant (22- and 12-fold, respectively) potency increases against the 3D7 and K1 strains, respectively, in comparison with artesunate.

© 2012 Elsevier Inc. All rights reserved.

1. Introduction

Each year roughly 800,000 people die of malaria, with 95% being African children [1]. The development and spread of multidrug resistant (MDR) *Plasmodium falciparum* has led to the adoption of artemisinin-based combination therapies (ACTs) as the first-line treatment for *falciparum* malaria in most malaria-endemic countries of the world [2]. However, the recently confirmed emergence of artemisinin resistance in western Cambodia is a major threat for current initiatives to control and eliminate malaria [3–5]. While artemisinin resistance has not yet spread to other areas [6], the World Health Organization (WHO) is coordinating a large-scale elimination campaign in this region aiming to contain the spread of resistance [7,8].

The ACTs combine fast-acting artemisinin (ART) derived drugs with other antimalarials possessing longer half-lives such as mefloquine. Because the utility of artemisinin is limited by its solubility in both oil and water, this sesquiterpene has been structurally modified by derivatization into short-chain oil soluble ether derivatives of dihydroartemisinin (DHA, **2**), such as artemether (AM, **2a**) and arteether (AE, **2b**), and the water soluble sodium artesunate (AS, **2c**) (Fig. 1).

Thus, all derivatives currently in use are either alkyl acetals or an ester acetal derivative of dihydroartemisinin (DHA, **2**). The


problem with these semi-synthetic compounds, however, is their short pharmacological half-lives, a reflection of their acid lability, and facile metabolism to DHA [9–12]. In particular, artesunate is hydrolytically unstable, even at neutral pH, and has a half-life of only a few minutes [13].

A large amount of work has been carried out with the aim of generating new derivatives [14–16]. Artemisone (Fig. 2) is thus far the only second-generation semi-synthetic artemisinin derivative that has been found suitable for further clinical development, progressing through Phase II but showing no major benefits over existing derivatives [17]. Arterolane [18], a synthetic ozonide (Fig. 2, OZ277) has a longer half-life, is fast acting, well tolerated, and effective. It is now in Phase III clinical trials in combination with piperazine [19,20]. OZ439 (Fig. 2), a purely synthetic ozonide, is a drug candidate designed to provide a single-dose oral cure in humans. It has successfully completed Phase I clinical trials, where it was shown to be safe at doses up to 1.6 g, and is currently undergoing Phase IIa trials in malaria patients [21]. In *in vitro* and *vivo* animal studies, OZ439 has been reported to have a better anti-malarial drug profile than OZ277 and all other semi-synthetic artemisinin derivatives. On the basis of their structural differences, it is believed that these synthetic ozonides may replace the standard artemisinins if they become obsolete [17]. Nevertheless, the shortcomings of the current drugs, the emergence of *P. falciparum* resistance to the artemisinin class of compounds and the fact that the mechanism by which the parasite acquires resistance is still largely unknown, warrant the search for new classes or derivatives.

In this communication, we report the synthesis of series of alkyl/aryl esters and their antimalarial activity as well as cytotoxicity.

* Corresponding author. Address: Pharmaceutical Chemistry, School of Pharmacy, North-West University, Private Bag X 6001, Internal Box 304, Potchefstroom 2520, South Africa. Fax: +27 18 299 4243.

E-mail address: david.nda@nwu.ac.za (D.D. N'Da).



Artemisinin 1

Fig. 1. Structures of artemisinin 1 and its clinically used derivatives; dihydroartemisinin 2, artemether 2a, arteether 2b and sodium artesunate 2c.




Fig. 2. Structures of the semi-synthetic artemisinin derivative artemisone and the synthetic ozonide OZ277 and OZ439.

Previously synthesized aminoethylethers of artemisinin were also screened alongside the esters to highlight their inhibitory potential against a variety of *P. falciparum* strains.

2. Materials and methods

2.1. Materials

All the acyl chlorides used in the synthesis were purchased from Fluka (Johannesburg, South Africa). Anhydrous dichloromethane was purchased from Sigma–Aldrich (Johannesburg, South Africa). Dihydroartemisinin (α and β racemates) was purchased from HuBei Enshi TianRanYuan Science and Technology Herbal Co., Ltd. (Hangzhou, China). HPLC grade methanol was obtained from Labchem Ltd. (Johannesburg, South Africa). All the reagents and chemicals were of analytical grade.

2.2. General procedures

Thin-layer chromatography (TLC) was performed using silica gel plates (60F₂₅₄ Merck). Preparative flash column chromatography was carried out on silica gel (230–240 mesh, G60 Merck) and silica gel 60 (70–230 mesh ASTM, Fluka).

The ¹H and ¹³C NMR spectra were recorded on a Bruker Avance III 600 spectrometer (at a frequency of 600.17 and 150.913 MHz, respectively) in deuterated chloroform (CDCl₃). Chemical shifts are reported in parts per million (δ ppm) using tetramethylsilane (TMS) as internal standard. The splitting pattern abbreviations are as follows: s (singlet), d (doublet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets), t (triplet), td (triplet of doublets), tt (triplet of triplet) and m (multiplet).

Low resolution mass spectra (LRESI) were collected on the Thermo Finnigan LXQ ion trap mass spectrometer in ESI mode. NaCl was added as a modifier to stabilize the compounds in ESI mode. The high resolution ESI (HRESI) mass spectra (MS) were recorded on a Thermo Electron DFS LXQ ion mass spectrometer in ESI mode and [M + Na]⁺ were recorded.

2.3. High performance liquid chromatography (HPLC)

The HPLC system consisted of an Agilent 1100 series auto sampler, Agilent 1100 series variable wave detector (VWD) and Agilent

1100 series isocratic pump. A Zorbax Eclipse XDB C18, 5 μ m (150 $\times$ 4.60 mm) column was used and the Agilent Chemstation reverse A08.03 for LC systems software package for data analysis. The compounds were quantified using a gradient method (A = 0.2% triethylamine in H₂O, pH 7.0, B = acetonitrile) at a flow rate of 1 ml/min with 20 μ l standard sample injections. The gradient consisted of 25% of solvent B (ACN) until 1 min, then increased linearly to 95% of B after 8 min, and held for 15 min, where after the instrument was re-equilibrated to the starting conditions for 5 min. A calibration plot of peak area versus drug concentration for each compound showed excellent linearity ($0.993 < r^2 \leq 1$ over the concentration range (0–2000 μ g/ml) employed for the assays. The absorption maximum for dihydroartemisinin and all its derivatives was at 205 nm; this wavelength was consequently used for the HPLC detection.


3. Experimental procedures

3.1. Synthesis of esters 11–18

The synthesis of artemisinin esters is depicted in Scheme 1 and was achieved as follows: dihydroartemisinin **2** (7 mmol) and acyl/aryl chlorides **3–10** (14 mmol, 2.0 equiv.) were dissolved in anhydrous dichloromethane (65 ml) together with triethylamine (14 mmol, 2.0 equiv.) and was stirred at room temperature for 24 h. The progress of the reaction was monitored by thin layer chromatography (TLC). After completion, the reaction mixture was evaporated to dryness *in vacuo*. The resulting residue was purified by flash chromatography using dichloromethane. All the synthesized compounds were solids, except **17** and **18**, which were oils. ¹H and ¹³C NMR chemical shifts as well as low and high resolution MS data of compounds **11–18** are reported.

3.1.1. 10 α -Dihydroartemisiny-propanoate 11

Yield: 47.2%; off-white powder; mp: 70–72 °C; ¹H NMR (600 MHz, CDCl₃): δ 6.16 (s, 1H, H-10), 5.51 (s, 1H, H-12), 2.09–1.95 (m, 2H, H-18), 2.59–1.74 (m, 5H, H-5a, -9, -8a and H-8), 2.16–1.96 (m, 2H, H-7), 1.88 (ddd, J = 25.2, 14.5, 10.9 Hz, 1H, H-6), 1.74–1.10 (m, 10H, H-14, -4, -5 and H-19), 0.98 (d, J = 10.5 Hz, 3H, H-16), 0.88 (d, J = 10 Hz, 3H, H-15); ¹³C NMR (151 MHz, CDCl₃) δ 165.5 (C-17), 134.94 (C-3), 108.07 (C-10), 104.48 (C-12), 68.10



Scheme 1. A general reaction scheme to illustrate the synthesis of 10-alkyl/aryl esters **11–18** of artemisinin from dihydroartemisinin and various acyl/aryl chlorides. Reagents and conditions: (a) dihydroartemisinin **2**, acyl/aryl chlorides **3–10**, dichloromethane, room temperature, 24 h.

(C-12a), 51.39 (C-5a), 44.39 (C-8a), 38.68 (C-4), 37.43 (C-9), 36.18 (C-7), 34.06 (C-6), 30.31 (C-18), 29.95 (C-14), 28.88 (C-8), 25.82 (C-5), 20.25 (C-15), 16.15 (C-16), 10.92 (C-19); LRESI *m/z*: 363 (M + 23, 50%); HRESI *m/z*: 363.1700 (M + 23) (M + 23, C₁₈H₂₈O₆Na, 363.1784 calc.).

3.1.2. 10 α -Dihydroartemisinyl butanoate 12

Yield: 18.7%; off-white powder; mp: 60–63 °C; ¹H NMR (600 MHz, CDCl₃): δ 5.78 (d, *J* = 9.8 Hz, 1H, H-10), 5.42 (s, 1H, H-12), 2.64–2.24 (m, 3H, H-5a and H-18), 2.09–1.92 (m, 1H, H-4a), 1.90–1.81 (m, 1H, H-9), 1.8–1.15 (m, 14H, H-8a, -8, -5, 4b, -6, -7, -14 and H-19), 1.06–0.88 (m, 6H, H-16 and H-20), 0.82 (d, *J* = 7.1 Hz, H-15); ¹³C NMR (151 MHz, CDCl₃): δ 172.41 (C-17), 104.42 (C-3), 91.63 (C-10), 91.47 (C-12), 80.14 (C-12a), 77.22 (C-5a), 77.00 (C-8a), 77.00 (C-4), 37.25 (C-9), 36.19 (C-7), 34.08 (C-6), 31.81 (C-18), 25.96 (C-14), 24.56 (C-8), 21.99 (C-5), 20.21 (C-15), 18.15 (C-19), 13.63 (C-16), 12.1 (C-20); LRESI *m/z*: 377 (M + 23, 30%); HRESI *m/z*: 377.1935 (M + 23) (M + 23, C₁₉H₃₀O₆Na, 377.1940 calc.).

3.1.3. 10 α -Dihydroartemisinyl octanoate 13

Yield: 65.7%, clear oil, ¹H NMR (600 MHz, CDCl₃): δ 5.77 (d, *J* = 9.9 Hz, 1H, H-10), 5.42 (s, 1H, H-12), 2.62–2.46 (m, 1H, H-5a), 2.42–2.27 (m, 3H, H-18 and H-4a), 2.01 (m, 1H, H-9), 1.92–1.81 (m, 1H, H-4b), 1.79–1.66 (m, 2H, H-19), 1.66–1.51 (m, 4H, H-8 and H-7), 1.49–1.36 (m, 4H, H-8a, H-6 and H-14), 1.35–1.19 (m, 10H, H-5 and H-20), 1.1–0.95 (m, 3H, H-16), 0.9–0.74 (m, 6H, H-15 and H-21); ¹³C NMR (151 MHz, CDCl₃): δ 172.60 (C-17), 104.43 (C-3), 91.63 (C-10), 91.48 (C-12), 80.15 (C-12a), 77.22 (C-5a), 77.00 (C-8a), 77.00 (C-4), 37.26 (C-9), 36.22 (C-7), 34.33 (C-6), 34.09 (C-18), 31.82 (C-6), 31.63 (C-19), 29.03 (C-14), 25.96 (C-8), 24.62 (C-5), 22.57 (C-15), 22.00 (C-20), 14.05 (C-16), 12.11

(C-21); LRESI *m/z*: 433 (M + 23, 100%); HRESI *m/z*: 433.2662 (M + 23) (M + 23, C₂₃H₃₈O₆Na, 433.2566 calc.).

3.1.4. 10 α -Dihydroartemisinyl decanoate 14

Yield: 78.45%, clear oil, ¹H NMR (600 MHz, CDCl₃): δ 5.77 (d, *J* = 9.8 Hz, 1H, H-10), 5.42 (s, 1H, H-12), 2.62–2.45 (m, 3H, H-5a), 2.42–2.27 (m, 3H, H-18 and H-4a), 2.01 (d, *J* = 14.5 Hz, 1H, H-4b), 1.93–1.83 (m, 1H, H-9), 1.79–1.66 (m, 2H, H-3'), 1.66–1.51 (m, 5H, H-6, -7 and H-7), 1.50–1.34 (m, 5H, H-8a, H-19 and H-14), 1.34–1.15 (m, 14H, H-5 and H-20), 1.05–0.90 (m, 3H, H-16), 0.9–0.76 (m, 6H, H-15 and H-21); ¹³C NMR (151 MHz, CDCl₃): δ 172.51 (C-17), 104.25 (C-3), 91.45 (C-10), 91.18 (C-12), 80.05 (C-12a), 77.96 (C-5a), 77.05 (C-8a), 77.02 (C-4), 37.96 (C-9), 36.37 (C-7), 34.48 (C-6), 34.19 (C-18), 31.92 (C-6), 31.79 (C-20), 29.25 (C-14), 25.56 (C-8), 24.54 (C-5), 21.57 (C-15), 21.00 (C-19), 14.85 (C-16), 10.11 (C-21); LRESI *m/z*: 461 (M + 23, 20%); HRESI *m/z*: 461.2875 (M + 23) (M + 23, C₂₅H₄₂O₆Na, 461.2879 calc.).

3.1.5. 10 α -Dihydroartemisinyl benzoate 15

Yield: 70.5%; clear crystal; mp: 115–18 °C; ¹H NMR (600 MHz, CDCl₃): δ 8.09 (dd, *J* = 8.2 and 1.0 Hz, 2H, H-19), 7.60–7.48 (m, 1H, H-21), 7.42 (t, *J* = 7.8 Hz, 2H, H-20), 5.98 (d, *J* = 9.8 Hz, 1H, H-10), 5.50 (s, 1H, H-12), 2.84–2.60 (m, 1H, H-9), 2.36 (ddd, *J* = 17.7, 13.9 and 4.0 Hz, 1H, H-8a), 2.02 (ddd, *J* = 14.6, 4.6 and 3.1 Hz, 1H, H-5a), 1.94–1.57 (m, 2H, H-4), 1.57–1.16 (m, 8H, H-6, -7, -8 and H-14), 1.14–0.7 (m, 8H, H-5, -15 and H-16); ¹³C NMR (151 MHz, CDCl₃): δ 165.27 (C-17), 133.27 (C-21), 130.09 (C-18), 129.58 (C-19), 128.26 (C-20), 104.40 (C-3), 92.49 (C-10), 91.56 (C-12), 80.17 (C-12a), 51.62 (C-5a), 45.31 (C-8a), 37.25 (C-4), 36.22 (C-9), 34.09 (C-7), 31.96 (C-6), 25.93 (C-14), 24.55 (C-8), 22.03 (C-5), 20.21 (C-15), 12.21 (C-16); LRESI *m/z*: 411 (M + 23, 20%); HRESI *m/z*: 411.1773 (M + 23) (M + 23, C₂₂H₂₈O₆Na, 411.1784 calc.).

3.1.6. 10 α -Dihydroartemisinyl 4-nitrobenzoate 16

Yield: 94%; yellow solid; mp: 94–98 °C; ¹H NMR (600 MHz, CDCl₃): δ 8.27 (s, 4H, H-19 and H-20), 6.00 (d, *J* = 9.8 Hz, 1H, H-10), 5.51 (s, 1H, H-12), 2.84–2.64 (m, 1H, H-9), 2.37 (dt, *J* = 14.1 and 3.7 Hz, 1H, H-5a), 1.94–1.60 (m, 2H, H-4), 1.57–1.24 (m, 8H, H-6, -7, -8 and H-14), 1.11–0.81 (m, 8H, H-5, -15 and H-16); ¹³C NMR (151 MHz, CDCl₃): δ 163.49 (C-17), 150.76 (C-21), 135.03 (C-18), 131.21 (C-19), 123.5 (C-20), 104.55 (C-3), 93.37 (C-10), 91.69 (C-12), 80.10 (C-12a), 51.58 (C-5a), 45.27 (C-8a), 37.28 (C-4), 36.20 (C-9), 34.06 (C-7), 31.89 (C-6), 25.90 (C-14), 24.56 (C-8), 22.03 (C-5), 20.20 (C-15), 12.22 (C-16); LRESI *m/z*: 456 (M + 23, 40%); HRESI *m/z*: 456.1808 (M + 23) (M + 23, C₂₂H₂₇NNaO₈, 456.1634 calc.).

3.1.7. 10 α -Dihydroartemisinyl 2-(acetyloxy) benzoate 17

Yield: 84.5%; off-white solid; mp: 80–83 °C; ¹H NMR (600 MHz, CDCl₃): δ 8.09 (dd, *J* = 17.7 and 1.6 Hz, 1H, H-19), 7.86 (ddd, *J* = 17.7, 7.9 and 1.6 Hz, 1H, H-21), 7.55 (td, *J* = 7.9 and 1.7 Hz, 1H, H-22), 7.30 (td, *J* = 7.7 and 0.9 Hz, 1H, H-20), 5.98 (d, *J* = 9.8 Hz, 1H, H-10), 5.48 (s, 1H, H-12), 2.73–2.56 (m, 1H, H-9), 2.41–2.22 (m, 4H, H-8a and H-25), 2.09–1.96 (m, 1H, H-5a), 1.92–1.84 (m, 1H, H-4a), 1.80–1.54 (m, 4H, H-7 and H-8), 1.54–1.20 (m, 3H, H-6 and H-14), 0.99–0.92 (m, 3H, H-15), 0.86 (d, *J* = 7.1 Hz, H-3); ¹³C NMR (151 MHz, CDCl₃): δ 169.93 (C-24), 163.10 (C-17), 151.01 (C-23), 134.21 (C-21), 132.29 (C-19), 125.95 (C-20), 124.44 (C-22), 122.80 (C-18), 104.4 (C-3), 92.54 (C-10), 91.51 (C-12), 80.07 (C-12a), 53.42 (C-5a), 51.56 (C-8a), 45.33 (C-4), 37.29 (C-9), 36.23 (C-7), 34.09 (C-6), 32.01 (C-14), 25.56 (C-8), 21.07 (C-5), 20.22 (C-15), 12.20 (C-16); LRESI *m/z*: 469 (M + 23, 100%); HRESI *m/z*: 469.1833 (M + 23) (M + 23, C₂₄H₃₀O₈Na, 469.1838 calc.).

3.1.8. 10 α -Dihydroartemisinyl 2-phenylacetate 18

Yield: 40.1%; off-white solid; mp: 101–105 °C; ^1H NMR (600 MHz, CDCl_3): δ 7.36–7.19 (m, 5H, H-20, 21 and H-22), 5.76 (d, J = 9.8 Hz, 1H, H-10), 5.42 (s, 1H, H-12), 3.77–3.55 (m, 1H, H-18), 2.64–2.43 (m, 1H, H-5a), 2.36 (td, J = 14.1 and 3.8 Hz, 2H, H-4), 1.77–1.62 (m, 1H, H-9), 1.62–1.53 (m, 8H, H-6, -7, -8 and H-14), 1.5–1.15 (m, 3H, H-16), 0.89 (d, J = 7.1 Hz, 1H, H-15); ^{13}C NMR (151 MHz, CDCl_3): δ 170.35 (C-17), 133.58 (C-19), 129.39 (C-20), 128.50 (C-21), 127.13 (C-22), 104.46 (C-3), 92.20 (C-10), 91.53 (C-12), 80.12 (C-12a), 51.54 (C-5a), 45.23 (C-8a), 41.28 (C-18), 37.23 (C-4), 36.20 (C-9), 34.05 (C-7), 31.85 (C-6), 25.96 (C-14), 24.56 (C-8), 21.94 (C-5), 20.19 (C-15), 11.88 (C-16); LRESI m/z : 425 (M + 23, 40%); HRESI m/z : 425.1938 (M + 23) (M + 23, $\text{C}_{23}\text{H}_{30}\text{O}_6\text{Na}$, 425.1940 calc.).

3.2. Synthesis of 10-aminoethylethers of artemisinin 19–29

The 10-aminoethylethers of artemisinin **19–29** were previously synthesized using a two-step process using a method reported by Li et al. [15]. The synthesis and characterization of these compounds have been reported elsewhere [22] and their structures are delineated in Fig. 3.

3.3. Physicochemical properties

3.3.1. Aqueous solubility (S_w)

The aqueous solubility (S_w) of crystalline compounds **11**, **12**, and **15–18** as well as DHA **2** were obtained by preparing solutions in PBS (pH 5.5 and pH 7.4). The slurries were stirred in a water bath at 37 °C for 24 h. An excess of solute was present at all times to provide saturated solutions. After 24 h, the solutions were filtered and analyzed directly by HPLC to determine the concentration of solute dissolved in the solvent. For the oils **13** and **14**, after 24 h stirring, the mixtures were allowed to stand at room temperature then the aqueous layers were carefully separated and analyzed by HPLC [23]. The experiment was performed in triplicate for each

compound. The average results are reported in Table 1. Furthermore, solubility in *n*-octanol was used to mimic the solubility in a lipophilic environment. The lipid solubility (S_L) values were deduced from the equation $\log S_L = \log D + \log S_w$, where S_w and $\log D$ are experimental.

3.3.2. Distribution coefficient ($\log D$)

Equal volumes of *n*-octanol and PBS (pH 5.5 and 7.4) were mixed with vigorous stirring for at least 24 h. 2 mg of each derivative was dissolved in 0.75 ml of this solution, the solution was then stoppered and agitated for 10 min in 2 ml graduated tubes (0.5 ml division). Subsequently 0.75 ml of pre-saturated buffer was transferred to the tubes containing the before mentioned solutions. The tubes were stoppered and agitated for 45 min after which they were centrifuged at 4 000 rpm (1503 g) for 30 min. The *n*-octanol and aqueous phases were allowed to separate at room temperature for 5 min, where after their volume ratio (v/v; *n*-octanol:buffer) was determined. The volume ratio was found in all cases to be 1. The *n*-octanol and aqueous phases were then analyzed by HPLC. From this data, the concentrations of the derivative in both phases were determined. The $\log D$ values were calculated as logarithmic ratios of the concentrations in the *n*-octanol phase compared to the concentrations in the buffer [23]. The experiment was performed in triplicate and the results, expressed as means, are listed in Table 1. As oxalate salts, the aminoethylethers **19–29** were not subjected to experimental aqueous solubility and distribution coefficient determinations.


3.4. Methodology for in vitro biological evaluation

3.4.1. Determination of antimalarial effective concentration (EC)

The esters and aminoethylethers of artemisinin were screened against the chloroquine-sensitive (CQS, 3D7) and chloroquine-resistant (CQR, K1) strains of *P. falciparum*. Continuous *in vitro* cultures of asexual erythrocyte stages of *P. falciparum* were maintained using a modified method of Trager and Jensen [24]. Asynchronous parasites were grown in the presence of fresh group O-positive erythrocytes (Lifeblood, Memphis, TN) in Petri dishes at a hematocrit of 4–6% in RPMI-based medium consisting of RPMI 1640 supplemented with 0.5% AlbuMAX II, 25 mM HEPES, 25 mM NaHCO_3 (pH 7.3), 100 $\mu\text{g}/\text{ml}$ hypoxanthine, and 5 $\mu\text{g}/\text{ml}$ gentamicin. Cultures were incubated at 37 °C in a gas mixture of 90% N_2 , 5% O_2 , and 5% CO_2 . For EC_{50} determinations, 20 μl of RPMI 1640 with 5 $\mu\text{g}/\text{ml}$ gentamicin were dispensed per well in an assay plate (384-well microtiter plate, clear-bottom, tissue-treated). Next, 40 nl of each compound, previously serial diluted in a separate 384-well white polypropylene plate, were dispensed in the assay plate, and then 20 μl of a synchronized culture suspension (1% rings, 10% hematocrit) were added per well to make a final hematocrit and parasitemia of 5% and 1%, respectively. Assay plates were incubated for 72 h, and the parasitemia was determined by a method previously described [25]. Briefly, 10 μl of 10X Sybr Green I, 0.5% v/v Triton, and 0.5 mg/ml saponin solution in RPMI were added per well. Assay plates were shaken for 30 s, incubated in the dark for 4 h, and then read with the Envision spectrofluorometer at Ex/Em 485 nm/535 nm. EC_{50} s were calculated using proprietary software developed in house (RISE) in the Pipeline Pilot environment that pools data from all replicates of the experiment and fits a consensus model.

3.4.2. In vitro cytotoxicity against HEK293 and HEP G2 cells

HEK293 and HepG2 cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and were cultured according to recommendations. Cell culture media were purchased from ATCC. Cells were routinely tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit



10 β -aminoethylethers **19–29**

Comp.	R'	Comp.	R'
19		25	
20		26	
21		27	
22		28	
23		29	
24			

Fig. 3. Structures of 10-aminoethylethers of artemisinin **19–29**.

Table 1

Aqueous solubility, distribution coefficients and lipid solubility of esters 11–18. The aqueous solubility (S_W) was determined in PBS (pH 5.5 and 7.4) at 37 °C after incubation in a water bath with stirring for 24 h; distribution coefficient ($\log D$) was obtained after *n*-octanol/PBS (pH 5.5 and 7.4) partition, and lipid solubility (S_L) was deduced from experimental S_W and S_L .

Comp.	J (Hz) ^a	Isomer	$S_{W7.4}$ (μ M) ^b	SD	$\log D_{7.4}$ ^c	$S_{L7.4}$ (μ M) ^d	$S_{W5.5}$ (μ M) ^a	SD	$\log D_{5.5}$ ^a	$S_{L5.5}$ (μ M) ^b
DHA 2	ND		1.2	0.09	0.1	1.5	3.2	0.08	0.3	6.4
11	ND		0.3	0.01	0.8	1.9	0.4	0.04	0.3	0.8
12	9.8	α	0.3	0.01	0.7	1.5	0.9	0.01	0.7	2.3
13	9.9	α	0.2	0.04	0.9	1.6	0.5	0.05	0.2	0.8
14	9.8	α	0.5	0.01	0.9	4.0	0.5	0.03	0.9	4.0
15	9.8	α	0.3	0.07	0.5	1.0	0.6	0.07	0.2	1.0
16	9.8	α	1.0	0.08	0.4	2.5	1.4	0.05	0.6	5.6
17	9.8	α	0.7	0.02	0.3	1.4	0.9	0.03	0.2	1.4
18	9.8	α	0.7	0.01	0.7	3.5	0.9	0.01	0.3	1.8

^a Coupling constant (J) between H-10 and H-9.

^b Experimental aqueous solubility (S_W), each value represents the mean of three independent measurements.

^c Experimental distribution coefficient, $\log D$ (*n*-octanol: PBS, pH 5.5 and 7.4), each value represents the mean of three independent measurements.

^d Lipid solubility (S_L) deduced using $\log S_L = \log D + \log S_W$ where $\log D$ and S_W are experimental data; standard deviation (SD).

(Lonza). Exponentially growing cells were plated in Corning 384 well white custom assay plates, and incubated overnight at 37 °C in a humidified, 5% CO₂ incubator. DMSO inhibitor stock solutions were added the following day to a top final concentration of 25 μ M, 0.25% DMSO and then diluted 1/3 for a total of ten testing concentrations. Cytotoxicity was determined following a 72-h incubation using Promega Cell Titer Glo Reagent according to the manufacturer's recommendation. Luminescence was measured on an Envision plate reader (Perkin Elmer). EC₅₀s were calculated using proprietary software developed in house (RISE) in the Pipeline Pilot environment that pools data from all replicates of the experiment and fits a consensus model.

3.4.3. Dose–response curve fitting

Dose–response curves were calculated from percent activity values and log₁₀-transformed concentrations, the proprietary robust interpretation of screening experiments (RISE) application written in Pipeline Pilot (Accelrys, v. 8.5) and the R program [26]. Briefly, non-linear regression was performed using the R *drc* package with the four-parameter log–logistic function (LL2.4) [27]. The data for all replicates for each compound was fit three separate times by varying the parameters that were fixed during regression: (1) all parameters free, (2) high response fixed to 100, (3) low response fixed to 0. The best fit from these three nested models was selected using the *anova.drc* function. 95% confidence intervals were produced based upon this fit.

Dose–response curves were assigned a quality score according to the following heuristic. Compounds which failed to fit to any curve, or with curves having efficacy <25% or >150% or hill slope <0.5 or >25 were designated class 'D1'. Compounds passing this first criteria with curves having efficacy <50%, calculated EC₅₀ > the highest concentration tested, lower and upper EC₅₀ confidence limits > 10-fold EC₅₀, or slope at the highest concentration tested >75% (non-saturating) were designated class 'C1'. Compounds passing previous criteria with curves having lower and upper EC₅₀ confidence limits > 5-fold EC₅₀ or slope at the highest concentration tested >25% (not completely saturating) were designated class 'B1'. All remaining curves were designated 'A1', which is indicative of ideal, well-behaved sigmoidal response. Curves that were inverted (activity decreased as concentration increased) were prefixed with the letter 'N', such as 'NA1'. In tabulating data, EC₅₀ values are only called for A1 and B1 class curves with a single value and error being provided for A1 curves and a range provided for B1 curves. C1 and D1 curves were assigned an arbitrary value of either greater than the highest concentration tested or lower than the lowest concentration tested, when appropriate. All the biological results are summarized in Table 2.

4. Results and discussion

4.1. Chemistry

The esters were obtained by acylation of C-10 of dihydroartemisinin. The configuration at that stereocenter was assigned based on the vicinal coupling constant $J_{H-9:H-10}$ [28]. A large coupling constant (9–10 Hz) is generally found for the 10 α -isomer [29], indicating the relative *trans* configuration. The 10 β -isomer, on the other hand has a smaller coupling constant (3.6–5 Hz) [30]. Thus, the esters 12–18, all with $J_{H-9:H-10}$ values of 9.8 Hz were the 10 α -isomers. Compound 11 showed no detectable coupling constant thus, the stereochemistry at the C-10 could not be deduced on the basis of that parameter.

In the ¹H spectra of these 10 α -esters, the doublet due to resonance of H-10 appeared downfield compared to the singlet of H-12. This as the result of the electron-withdrawing effect of the ester carbonyl. In the ¹³C spectra, the presence of carbonyl carbon C-17 is noticeable at 170–160 ppm. The C-10, which usually resonates at ~99 ppm for DHA, was further shielded for these compounds resulting in the signal shifting up field to 92–90 ppm. All signals due to DHA's carbons were also found in the spectra of the esters confirming the presence of that moiety in their structures.

The chemical structures of the title esters 11–18 were further confirmed by MS analysis. LRESI data showed the molecular ions $M + 23$ m/z of compounds 11, 12, 13, 14, 15, 16, 17 and 18 at 363, 377, 433, 461, 411, 455, 425 and 469, respectively. The HRESI–MS confirmed the exact mass of 11 [363.1700], which corresponds to the formula C₁₈H₂₈O₆Na, of 12 [377.1935] for C₁₉H₃₀O₆Na, of 13 [433.2662] for C₂₃H₃₈O₆Na, of 14 [461.2875] for C₂₅H₄₂O₆Na, of 15 [411.1773] for C₂₂H₂₈O₆Na, of 16 [456.1808] for C₂₂H₂₇O₈Na, of 17 [469.1838] for C₂₄H₃₀O₈Na, and of 18 [425.1938] for the formula C₂₃H₃₀O₆Na.

The 10-aminoethylethers 19–29 were all 10 β -isomers [22].

4.2. Aqueous solubility and logD

Aqueous solubility and lipophilicity influence the way a molecule passes through biological membranes and barriers to ultimately enter the systemic circulation. Drugs must thus possess balanced lipophilic/hydrophilic properties to both permeate biological membranes and be taken up for systemic circulation. The logarithm of ratio of octanol solubility to water solubility ($\log P$) is absorption good measure of this balance with values between 0 and 5 being targeted, and 0–3 being ideal [31,32]. The distribution coefficient ($\log D$), a pH dependent version of the partition

Table 2

In vitro antimalarial activity of esters **11–18** and aminoethylethers **19–29** of artemisinin against 3D7 and K1 strains of *Plasmodium falciparum*, and their cytotoxicity against HEK293 and HepG2 cell lines. Cells were incubated with compounds at various concentrations for 72 h; antimalarial activity and cytotoxicity were determined using SYBR Green I-based fluorescence and CellTiter-Glo luminescent cell viability assays, respectively.

Comp.	Activity EC ₅₀ (nM) ^a		RI ^b	Cytotoxicity EC ₅₀ (μM) ^c		10 ³ × SI ₁ ^d	10 ³ × SI ₂ ^e
	3D7	K1		HEK293	HepG2		
11	3.1	0.3	0.1	>26.0	>26.0	>8.4	>8.4
12	13.3	6.2	0.5	>26.0	>26.0	>2.0	>2.0
13	9.4	5.0	0.5	>26.0	>26.0	>2.8	>2.8
14	21.3	17	0.8	>26.0	>26.0	>1.2	>1.2
15	3	0.9	0.3	>26.0	>26.0	>8.7	>8.7
16	3.1	1.1	0.4	>23.8	>23.8	>7.7	>7.7
17	5.1	3.3	0.7	>26.0	>26.0	>5.1	>5.1
18	2.4	0.5	0.2	>26.0	>26.0	>10.9	>10.9
19	8.7	3.1	0.4	>27.5	>27.5	>3.2	>3.2
20	14.8	6.3	0.4	>21.4	>21.4	>1.5	>1.5
21	10.1	5.5	0.6	>31.7	>31.7	>3.1	>3.1
22	11.3	6.6	0.6	>13.3	>13.3	>1.2	>1.2
23	11.3	4.1	0.4	>18.6	>18.6	>1.7	>1.7
24	7.9	3.6	0.5	>29.6	>29.6	>3.8	>3.8
25	9	5.8	0.6	>26.6	>26.6	>3.0	>3.0
26	22.1	26.1	1.2	>22.7	>22.7	>1.0	>1.0
27	23.7	10.8	0.5	>30.1	>30.1	>1.3	>1.3
28	7.9	4.0	0.5	>28.9	>28.9	>3.7	>3.7
29	6.8	2.4	0.4	>16.0	>16.0	>2.4	>2.4
AM 2a	166	1723.3	10.4	>26.0	>26.0	>0.2	>0.2
AS 2c	6.6	6.6	1	>26.0	>26.0	>3.9	>3.9

^a Effective concentration of compound inducing 50% reduction in parasitic cells count.

^b Effective concentration of compound selectively inducing 50% reduction in parasitic cells count in the presence of mammalian cells.

^c Resistance index (RI) = EC₅₀ K1/EC₅₀ 3D7.

^d Selectivity index (SI₁) = EC₅₀ HEK293/EC₅₀ 3D7.

^e Selectivity index (SI₂) = EC₅₀ Hep G2/EC₅₀ 3D7.

coefficient (logP) was determined experimentally in a phosphate buffer at two distinctive pH values (7.4 and 5.5), chosen to mimic the cytosolic and parasite digestive vacuole environments, respectively.

Overall the esters had aqueous solubility slightly lower than that of DHA, regardless of the medium. While this may not be significant enough to influence their relative absorption through biological membranes, it can be attributed to the fact that the hydrogen bonding polar site of DHA, is masked by a lipophilic group.

Comparison of *S_w*, log*D*, and *S_L* values in both media also revealed no significant differences among the esters. They all displayed comparable aqueous and lipid solubility as well as distribution coefficients in both environments. No significant structure-physicochemical property relationship could thus be deduced from this study.

4.3. *In vitro* antimalarial activity and cytotoxicity

The esters **11–18** and aminoethers **19–29** were tested *in vitro* against both the chloroquine sensitive (CQS) 3D7, and chloroquine resistant (CQR) K1 strains of *P. falciparum* (Table 2). Both compound-types were active against both the 3D7 and K1 strains. The esters were all significantly more potent than AM, up to 60- and 5000-fold against 3D7 and K1, respectively. The aminoethylethers also displayed significantly better potency than AM but to a lesser extent, 20- and 700-fold.

In comparison with artesunate, however, the behavior was quite different. Ester 14 and ethers 26 and 27 were 3-fold less potent than AS, while all other derivatives had comparable to AS against the 3D7 strain. This trend was also observed against the K1 strain. Ester 14 and ethers 26 and 27 were still less potent than AS but the remaining derivatives were either as active or more potent than the reference drug. Thus, against this strain, the esters were found still more active than the ethers. Compounds 11, 15, 16 and 18, all esters were distinctively the most active of all

artemisinin derivatives synthesized during this study. They were significantly more potent than AS against the K1 strain with 11 and 18 possessing 22- and 12-fold improvements, respectively. No SAR could be deduced with the esters due to limited structural diversity.

In the 10-aminoethylether series, ether **29** was the most active of all. It was as potent as AS against 3D7 and possessed a moderate potency improvement (~3-fold) against K1. Ether **26**, on the other hand was the least potent. It found 3-fold less potent than AS against both the 3D7 and K1 strains. The series may be divided into two sub-series viz. the monoamine series comprising ethers **19, 21, 24, 25, 28** and **29**, and the polyamine one including **20, 22, 23, 26** and **27**. Cloete et al. [22] reported the monoamine sub-series to be more active than the polyamine in screening against CQS D10 and CQR Dd2 strains. This was also the case against the 3D7 and K1 strains in this study. However, these ethers appear more active against D10 than 3D7, and K1 than Dd2. Average 3- to 6-fold and 5- to 10-fold variances were found between activity against D10 and 3D7, and K1 and Dd2, respectively, which shows that although both are considered to be CQ sensitive, these strains are still different cell lines and have different behaviors in the presence of the compounds. It is, thus, noteworthy that these 10-aminoethylethers of artemisinin are active against four different strains of *P. falciparum*.

Furthermore, the aminoethylethers are hydrophilic and weak bases able to undergo protonation at lower pH value such as that occurring in the parasitic digestive vacuole (pH~5.5), and thus accumulate in higher concentration by pH-trapping mechanism. One would then expect a synergism between the action inherent to the DHA endoperoxide and the pH-trapping mechanism to render these aminoethers more active than the esters, which lack the amine(s) for pH-trapping mechanism. However, the EC₅₀ data against both strains showed the opposite, confirming that the drug's absorption is dependent upon multiple physicochemical parameters [33].

To determine whether the synthesized compounds were selective in their action against the plasmodia cells, relative to host

cells, a selectivity index (SI) was determined for multiple mammalian cell types. All compounds 11–29 proved to be non-toxic to both HEK293 and HepG2 cells as can be seen from the high SI₁ and SI₂ values, all above 1000.

5. Conclusions

A series of 10 α -*n*-alkyl/aryl esters were synthesized through derivatization at C-10 of dihydroartemisinin. The structures of the compounds were verified and confirmed by NMR and MS analyses. The esters were subjected to distribution coefficient and aqueous solubility experimental determinations in both weakly acid (pH 5.5) and physiological (pH 7.4) media. The esters were found moderately less hydrophilic than DHA with comparable lipophilicity, and displayed similar distribution coefficients and aqueous solubility in both media. The esters were screened for antimalarial activity alongside 10-aminoethylethers of artemisinin against the CQS 3D7 and CQR K1 strains of *P. falciparum*. Both compound types were active with the esters having a moderate upper edge over the ethers. They possessed significant potency improvement over artemether against both strains, up to 500-fold on average. In comparison to artesunate, the majority of compounds possessed either similar or a higher degree of potency against both strains. The 10 α -*n*-propyl **11** and 10 α -benzyl **18** esters were the most potent of all synthesized derivatives with activity comparable to that of AS against 3D7 but more importantly by their significant potency (22- and 12-fold, respectively) over AS against the resistant strain K1. Short biological half-life is a feature common to ozonides. Thus, these two esters stand as good candidates to undergo pharmacokinetic study to ascertain whether they possess half-lives longer than those of the current clinically available artemisinin derivatives.

Acknowledgments

The authors thank the National Research Foundation (NRF) and the North-West University (NWU) for financial support.

References

- [1] L. Liu, H.L. Johnson, S. Cousens, J. Perin, S. Scott, J.E. Lawn, I. Rudan, H. Campbell, R. Cibulskis, M. Li, C. Mathers, R.E. Black, *Lancet* 379 (2012) 2151–2161. Epub 2012 May 11.
- [2] N.J. White, *Science* 320 (2008) 330–334.
- [3] A.M. Dondorp, F. Nosten, P. Yi, D. Das, A.P. Phyo, J. Tarning, K.M. Lwin, F. Ariey, W. Hanpithakpong, S.J. Lee, P. Ringwald, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S.S. An, S. Yeung, P. Singhasivanon, N.P.J. Day, N. Lindegardh, D. Socheat, N.J. White, *N. Engl. J. Med.* 361 (2009) 455–467.
- [4] H. Noedl, Y. Se, K. Schaecher, B.L. Smith, D. Socheat, M.M. Fukuda, *N. Engl. J. Med.* 359 (2008) 2619–2620.
- [5] H. Noedl, Y. Se, S. Sriwichai, K. Schaecher, P. Teja-Isavadharm, S. Bryan, R. Wiriya, B. Delia, S. Sittidech, M.M. Fukuda, D. Socheat, L.C. Thap, *Clin. Infect. Dis.* 51 (2010) e82–89.
- [6] H. Noedl, D. Socheat, W. Satimai, *N. Engl. J. Med.* 361 (2009) 540–541.
- [7] WHO World Health Organization, Development of a strategy towards elimination of *Plasmodium falciparum* parasites with altered responses to artemisinins, 2000.
- [8] WHO World Health Organization, Strategic Framework for Artemisinin Resistance Containment in Myanmar (MARC) 2011–2015, 2011.
- [9] A.J. Lin, D.L. Klayman, W.K. Milhous, *J. Med. Chem.* 30 (1987) 2147–2150.
- [10] V. Leskovac, A.D. Theoharides, *Comp. Biochem. Physiol.* 99 (1991) 383–390.
- [11] V. Leskovac, A.D. Theoharides, *Comp. Biochem. Physiol.* 99 (1991) 391–396.
- [12] J.K. Baker, J.D. McChesney, H.-T. Chi, *Pharm. Res.* 10 (1993) 662–666.
- [13] K.T. Batty, K.F. Ilett, T.M.E. Davis, *J. Pharm. Pharmacol.* 48 (1996) 22–26.
- [14] China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials, *J. Tradit. Chin. Med.* 2 (1982) 9–16.
- [15] Y. Li, Y.-M. Zhu, H.-J. Jiang, J.-P. Pan, G.-S. Wu, J.-M. Wu, *J. Med. Chem.* 43 (2000) 1635–1640; R.K. Haynes, H.-W. Chan, M.-K. Cheung, W.-L. Lam, M.-K. Soo, H.-W. Tsang, A. Voerste, I.D. Williams, *Eur. J. Org. Chem.* (2002) 113–132; S. Hindley, S.A. Ward, R.C. Storr, N.L. Searle, P.G. Bray, B.K. Park, J. Davies, P.M. O'Neill, *J. Med. Chem.* 45 (2002) 1052–1063; R.K. Haynes, H.-W. Chan, M.-K. Cheung, W.-L. Lam, M.-K. Soo, H.-W. Tsang, A. Voerste, I.D. Williams, *Eur. J. Org. Chem.* (2003) 2098–2114.
- [16] Few reviews on clinical use, chemistry, pharmacology, and mode of action S.R. Meshnick, *Int. J. Parasitol.* 32 (2002) 1655–1660; T. Gordi, E.-I. Lepist, *Toxicol. Lett.* 147 (2004) 99–107; G. PrayGod, A. de Frey, M. Eisenhut, *Malaria J.* 7 (2008) 210; D. Chaturvedi, A. Goswami, P.P. Sakia, N.C. Barua, P.G. Rao, *Chem. Soc. Rev.* 39 (2010) 435–454.
- [17] M. Enserink, *Science* 328 (2010) 846.
- [18] J.L. Vannerstrom, S. Arbe-Barnes, R. Brun, S.A. Charman, F.C. Chiu, J. Chollet, Y. Dong, A. Dorn, D. Hunziker, H. Matile, K. McIntosh, M. Padmanilayam, T.J. Santo, C. Scheurer, B. Scoreaux, Y. Tang, H. Urwyler, S. Wittlin, W.N. Charman, *Nature* 430 (2004) 900–904.
- [19] P. Olliaro, T.N.C. Wells, *Clin. Pharmacol. Ther.* 85 (2009) 584–595.
- [20] N. Valecha, S. Krudsood, N. Tangpukdee, S. Mohanty, S.K. Sharma, P.K. Tyagi, A. Anvikar, R. Mohanty, B.S. Rao, A.C. Jha, B. Shahi, J.P. Singh, A. Roy, P. Kaur, M. Kothari, S. Mehta, A. Gautam, J.K. Paliwal, S. Arora, N. Saha, *Clin. Infect. Dis.* (Epub 2012 June 18). doi:10.1093/cid/cis475.
- [21] S.A. Charman, S. Arbe-Barnes, I.C. Bathurst, R. Brund, M. Campbell, W.N. Charman, F.C.K. Chiu, J. Chollet, J.C. Craft, D.J. Creek, Y. Dong, H. Matile, M. Maurer, J. Morizzi, T. Nguyen, P. Papastogiannidis, C. Scheurer, D.M. Shackleford, K. Sriraghavan, L. Stingelin, Y. Tang, H. Urwyler, X. Wang, K.L. White, S. Wittlin, L. Zhou, J.L. Vannerstrom, *PNAS Early Ed.* (2011) 1–6.
- [22] T.T. Cloete, J.W. Breytenbach, C. de Kock, P.J. Smith, J.C. Breytenbach, D.D. N'Da, *Bioorg. Med. Chem.* 20 (2012) 4701–4709.
- [23] M. Steyn, D.D. N'Da, J.C. Breytenbach, P.J. Smith, S. Meredith, W.J. Breytenbach, *J. Pharm. Pharmacol.* 63 (2011) 278–286.
- [24] W. Trager, J.B. Jensen, *Science* 193 (1976) 673–675.
- [25] M. Smilkstein, N. Sriwilaijaroen, J.X. Kelly, P. Wilairat, M. Riscoe, *Antimicrob. Agents Chemother.* 48 (2004) 1803–1806.
- [26] R Development Core Team, R. A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria, 2011, ISBN 3-900051-07-0. <<http://www.R-project.org>>.
- [27] C. Ritz, J.C. Streibig, *Software* 12 (2005).
- [28] B. Venugopalan, P.J. Karnik, C.P. Bapat, D.K. Chatterjee, N. Iyer, D. Lepcha, *Eur. J. Med. Chem.* 30 (1995) 697–706.
- [29] A.J. Lin, A.B. Zikry, D.E. Kyle, *J. Med. Chem.* 40 (1997) 1396–1400.
- [30] A.J. Lin, M. Lee, D.L. Klayman, *J. Med. Chem.* 32 (1989) 1249–1252.
- [31] G. Caron, F. Raymond, P.-A. Carrupt, H.H. Girault, B. Testa, *Pharm. Sci. Technol. Today* 2 (1999) 327–335.
- [32] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, *Adv. Drug Deliv. Rev.* 46 (2001) 3–26.
- [33] F. Bigucci, T. Kamsu-Kom, C. Cholet, M. Besnard, D. Bonnet-Delpont, G. Ponchel, *J. Pharm. Pharmacol.* 60 (2008) 163–169.